NCT07114939 FTT PET/CT in Pancreatic Neuroendocrine Tumors
| NCT ID | NCT07114939 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Neuroendocrine Carcinoma Metastatic |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 12 participants in total. It began in 2025-10-01 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a novel PET imaging agent, \[18F\]FluorThanatrace (\[18F\]FTT). A total of 12 patients will be enrolled. Patients will undergo a study imaging assessment using a whole-body PET CT scanner. Dynamic images will be obtained beginning immediately prior to the administration of 10 mCi of \[18F\]FTT (±20%) for a total of 60 minutes. A static scan may subsequently be obtained up to 90 minutes post radiotracer injection, per the PI's discretion. \[18F\]FTT uptake will be measured on the PET scan and correlated with two molecular outcomes.
Eligibility Criteria
Inclusion Criteria: 1. Patients must be ≥ 18 years of age. 2. Clinical diagnosis of a metastatic or unresectable grade 1, grade 2 or grade 3 (G1/G2/G3) pancreatic neuroendocrine tumor. 3. Have at least one lesion on clinical imaging (e.g. CT/MRI/PET/CT/ultrasound) that is ≥ 1.5 cm in size. 4. Patients may be receiving any form of treatment or not be undergoing current treatment. 5. Willing to consent to use of tumor tissue (fresh frozen and/or clinical pathology specimens) collected as part of another study or biobank collection or clinical procedure. 6. Must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures. Exclusion Criteria: 1. Patients who have received liver directed therapy that treated all of their disease but whom have not yet had disease progression, per medical record review. 2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician. 3. Females who are pregnant or breastfeeding will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential prior to FTT injection. 4. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participating in the study. Only individuals (aged 18 or over) who can understand and give informed consent will be approached to participate in this study. Individuals who are considered to be mentally disabled will not be recruited for this study. All subjects must understand and be able to give informed consent. We will not be using specific methods to assess decisional capacity. Economically disadvantaged persons will not be vulnerable to undue influence, as this study offers no compensation. All individuals will be told that their choice regarding study participation will in no way change their access to clinical care. This should negate any undue influence or coercion. Children, fetuses, neonates or prisoners are not included in this research study.
Contact & Investigator
Austin Pantel, MD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT07114939 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neuroendocrine Carcinoma Metastatic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07114939 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07114939 currently recruiting?
Yes, NCT07114939 is actively recruiting participants. Contact the research team at erinschu@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07114939 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07114939 clinical trial?
NCT07114939 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Austin Pantel, MD at University of Pennsylvania. The trial plans to enroll 12 participants.